Qol Holdings (3034) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 period of FY2026, revenue increased, while Operating Income and Ordinary Income declined, making the deterioration in profitability the main issue. Revenue was ¥2160.2B (+9.0% YoY), Operating Income was ¥94.2B (-14.7%), and Ordinary Income was ¥94.9B (-16.5%). Net Income (quarterly net income attributable to owners of the parent) was ¥53.0B, compared with ¥57.7B in the previous year. The primary reason for the decline in profit was a change in the method of recording certain expenses in the Pharmaceutical Business, with expenses allocated to the second half of the fiscal year; the impact is expected to be smoothed over the full year.

Factors Affecting Performance

【Revenue】Revenue increased 9.0% YoY to ¥2160.2B. The primary factors were growth in the Pharmaceutical Business, the expansion of Daiichi Sankyo Espha’s ownership ratio from 51% to 80%, which broadened the scope of consolidation, and contributions from 3 active ingredients and 7 products launched in the previous fiscal year. The Pharmacy Business secured higher revenue due to an increase in per-prescription technical fees, while the BPO Business also remained solid as the number of CSO dispatches increased.

【Profit and Loss】Operating Income declined 14.7% YoY to ¥94.2B, while Ordinary Income declined 16.5% to ¥94.9B. The primary factor was a change in the method of recording certain expenses in the Pharmaceutical Business, a temporary factor that compressed Q3 profit due to the allocation of expenses to the second half of the fiscal year. Net extraordinary losses were limited to ¥1.1B, and the divergence between Ordinary Income and Net Income (-16.5% versus approximately +32.6%) was mainly attributable to the absence of the ¥12.4B extraordinary loss recorded in the same period of the previous year. In conclusion, the company recorded higher revenue but lower profit.

Segment Analysis

The core business is the Pharmacy Business, which generated revenue of ¥1325.2B, accounting for approximately 61% of total revenue. Operating Income was ¥68.7B (margin of 5.2%, down 2.3% YoY), reflecting a structure in which the decline in the number of prescriptions filled was offset by an increase in per-prescription technical fees. The BPO Business generated revenue of ¥115.6B and Operating Income of ¥13.5B (margin of 11.6%), securing the highest profit margin among the 3 segments; the increase in CSO dispatches drove higher revenue and profit. The Pharmaceutical Business posted strong revenue growth of 23.1% YoY to ¥730.7B, but Operating Income declined 26.0% to ¥40.2B, primarily due to the aforementioned change in the method of recording expenses. The decline in company-wide Operating Income resulted from both the slight decline in profit from the large-scale Pharmacy Business and the temporary compression of profit in the rapidly expanding Pharmaceutical Business.

Key Financial Indicators

Profitability: ROE 9.4%, Operating Income margin 4.4% (down from approximately 5.6% in the same period of the previous year)
Other: Gross profit margin 13.2%, SG&A expense ratio 8.8%
Financial soundness: Equity Ratio 36.2%
Earnings per share: Basic EPS ¥124.46 (¥94.22 in the previous year, +32.1%)

Cash Flow Analysis

Specific figures for Operating Cash Flow (OCF), investing cash flow, financing cash flow, and capital expenditures are not included in the disclosed data. From a profit-and-loss perspective, net income attributable to owners of the parent of ¥46.7B was only approximately 49.6% of Operating Income of ¥94.2B, while the ¥40.8B burden of income taxes and other taxes affects the conversion into cash generation. Current liabilities of ¥818.6B exceed current assets of ¥622.0B, indicating negative working capital. Although the increase in accounts payable to ¥402.9B supports liquidity, the importance of working capital management remains high.

Earnings Quality

The gap between Ordinary Income of ¥94.9B and consolidated Net Income of ¥53.0B was mainly attributable to the deduction of ¥40.8B in income taxes and other taxes and ¥6.3B in net income attributable to non-controlling interests. Net extraordinary losses were ¥1.1B, having a limited impact on pretax income of ¥93.8B; recurring operating performance continues to determine results. Non-operating income and expenses resulted in a net gain of only ¥0.7B, providing limited uplift from Operating Income to Ordinary Income. The change in the method of recording expenses in the Pharmaceutical Business represents a temporary distortion in the attribution of expenses to accounting periods, and should be noted as an item expected to be smoothed over the full year.

Earnings Forecast and Guidance

The cumulative Q3 progress rates against the full-year forecasts of revenue of ¥2800.0B, Operating Income of ¥155.0B, and Ordinary Income of ¥156.0B are 77.2%, 60.7%, and 60.8%, respectively. Compared with the standard progress rate of 75%, Operating Income and Ordinary Income are approximately 14pt below the benchmark, requiring a significant improvement in profitability in Q4. The company has explained that the concentration of expenses in the second half due to the change in the expense-recording method in the Pharmaceutical Business is the reason, with the impact expected to be smoothed over the full year.

Shareholder Returns

The Q2 dividend was ¥23.00 per share, and the full-year dividend forecast is ¥46.00. Based on the full-year earnings forecast, the Payout Ratio is calculated at approximately 24.7%, using the full-year dividend forecast of ¥46.00, forecast net income attributable to owners of the parent of ¥70.0B, and the average number of shares outstanding during the period of 37,531,994 shares. As the amount spent on share repurchases is not included in the disclosed data, the Total Return Ratio has not been calculated.

Catalysts

【Short Term】Abiraterone acetate is scheduled for a new launch in December 2025, and 4 prasugrel products are scheduled for new launches in March 2026, which are expected to contribute to revenue and profit in the Pharmaceutical Business. Progress in Q4 Operating Income, or the level required to achieve the full-year plan, will be a key focus.

【Long Term】Structural changes over the medium to long term include reviewing the store portfolio in the Pharmacy Business, expanding home-care and institutional dispensing services primarily in the Tokyo, Nagoya, and Osaka regions, and developing specialist-area medical representatives in the BPO Business, including oncology, immunology-related fields, and the central nervous system.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (retail)

Profitability and Return

Growth and Capital Efficiency

※Source: Company compilation

Risk Factors

1. Profit margin decline risk: While revenue increased 9.0%, Operating Income declined 14.7%, causing the Operating Income margin to fall to 4.4%. Given the low gross profit margin of 13.2%, the company’s structure is susceptible to procurement costs and revisions to drug prices and dispensing fees.

2. Regulatory revision risk: The Pharmacy Business is susceptible to revisions to dispensing fees, the selected medical treatment benefit system, and drug price revisions (scheduled for April 2025 and April 2026), and per-prescription technical fees may fluctuate from quarter to quarter.

3. Goodwill and intangible asset risk: Goodwill of ¥368.4B represents 65.0% of net assets of ¥566.5B, while intangible fixed assets account for 42.3% of total assets. If the earnings plans of acquired companies, including Daiichi Sankyo Espha, are not achieved, impairment risk could materialize.

Key Points in the Earnings Report

1. The full-year Operating Income progress rate is 60.7%, below the standard progress rate of 75%; therefore, the realization of improved profitability in Q4 is a key focus of the earnings report. The factor is the change in the method of recording expenses in the Pharmaceutical Business, with smoothing over the full year assumed.

2. Revenue in the Pharmaceutical Business increased 23.1% due to the expansion of the consolidated ownership interest in Daiichi Sankyo Espha (51%→80%), while Operating Income declined 26.0%. The simultaneous occurrence of higher revenue and lower profit indicates a change in the earnings structure.

3. With goodwill representing 65.0% and intangible fixed assets representing 42.3%, the asset composition has a high degree of dependence on M&A. Future impairment trends will therefore be a structural point of observation in assessing financial soundness.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,592–¥1,687 at ±1% for the cost of equity, and ¥1,635–¥1,643 at ±0.1 for ω.

Notes:

• Net Income is significantly compressed relative to Operating Income due to tax burden, acquisition-related expenses, and non-controlling interests (Net Income ÷ Operating Income 45%). This value reflects that compression at face value; if the factors are temporary, underlying earnings power may be higher.
• Goodwill represents a high proportion of net assets, and the assumptions would change substantially if impairment were incurred.
• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual income model (Ohlson type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI through integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was mixed: revenue expanded solidly, but core profitability weakened materially and the balance sheet remains acquisition-intangible heavy. Nine-month revenue rose 9.0% year on year to ¥216.0bn. Operating income declined 14.7% to ¥9.4bn despite the top-line growth. Ordinary income fell 16.5% to ¥9.5bn, confirming that the operating-profit pressure was not offset by non-operating items. Gross profit decreased 6.2% to ¥28.5bn as cost of sales increased faster than revenue. The gross margin contracted by 214bp year on year to 13.2% from 15.3%. SG&A expenses declined 1.4% to ¥19.1bn, and the SG&A-to-sales ratio improved by 93bp to 8.8%. This cost discipline partially mitigated gross-margin pressure, but was insufficient to prevent the operating margin from falling 121bp to 4.4%. The 4.4% EBIT margin is below the 5% efficiency threshold and indicates limited earnings protection against further reimbursement, procurement, or labor-cost pressure. Profit attributable to owners nevertheless rose 32.6% to ¥4.7bn. This improvement primarily reflects a sharp reduction in non-controlling interests and substantially smaller extraordinary losses, rather than an improvement in recurring operating earnings. The effective tax rate remained high at 43.5%, producing a tax burden of 0.498 and diluting conversion from pre-tax profit to net income. Reported annualized ROE was 11.0%, a respectable level, but it was supported by 2.76x financial leverage rather than a strong net margin. Liquidity is tight, with a 76.0% current ratio and ¥19.7bn negative working capital. The company is also exposed to material acquisition-accounting risk, as goodwill represents 65.0% of equity and intangible assets account for 42.3% of total assets. Against full-year guidance, Q3 cumulative sales progress is slightly ahead of the normal seasonal benchmark, while operating and ordinary-profit progress are substantially behind it. Achieving guidance therefore requires a pronounced Q4 recovery in operating profitability, making gross-margin stabilization and the pace of amortization-related earnings pressure central monitoring items.

Profitability Analysis

The supplied annualized DuPont decomposition produces ROE of 11.0%, comprising a 2.2% net profit margin, 1.839x asset turnover, and 2.76x financial leverage. The principal structural limitation is the low 2.2% net margin; revenue volume and asset utilization, rather than earnings retained per yen of sales, are doing most of the work in the return profile. Financial leverage is also a meaningful contributor to ROE, with the asset base financed by liabilities equal to 63.8% of total assets. Revenue growth of 9.0% did not translate into operating leverage because gross profit fell 6.2%. Cost of sales rose 11.7%, exceeding revenue growth, and reduced gross margin to 13.2% from 15.3%. SG&A expenses fell to ¥19.1bn from ¥19.4bn, demonstrating favorable overhead control; however, the 1.4% SG&A decline was modest relative to the ¥1.9bn decline in gross profit. Consequently, operating income fell to ¥9.4bn from ¥11.0bn and the operating margin compressed to 4.4% from 5.6%. The low gross margin is a material concern because a pharmacy and healthcare-services model requires sufficient gross-profit spread to absorb personnel, pharmacy-network, and administrative costs. Interest coverage of 36.63x remains strong, and the 0.996 interest burden shows that financing costs have not yet materially eroded EBIT. In contrast, the 0.498 tax burden is weak, with income tax expense of ¥4.1bn consuming 43.5% of pre-tax profit. Net income attributable to owners increased because non-controlling interests declined to ¥0.6bn from ¥2.2bn and extraordinary losses contracted to ¥0.2bn from ¥1.2bn. Thus, the improvement in reported owner earnings should not be interpreted as evidence that the underlying margin deterioration has reversed. Under JGAAP, goodwill is amortized and can depress operating income and net income relative to IFRS-based peers; the absolute goodwill balance of ¥36.8bn is therefore important when comparing profitability across accounting standards.

Growth Assessment

Revenue growth of 9.0% to ¥216.0bn indicates continued expansion in the underlying pharmacy and healthcare-related revenue base. However, the divergence between revenue growth and the 14.7% decline in operating income indicates that current growth is lower quality from a margin perspective. Gross profit fell to ¥28.5bn despite higher sales, showing that revenue expansion has not yet generated incremental gross-profit contribution. The full-year sales forecast is ¥280.0bn, and Q3 cumulative progress is 77.2%, modestly above the standard 75% Q3 pace. Full-year operating-income guidance is ¥15.5bn, with Q3 progress only 60.7%, or 14.3 percentage points below the standard pace. Ordinary-income progress is similarly 60.8% against a normal 75% Q3 benchmark. Profit attributable to owners has reached 66.7% of the ¥7.0bn full-year forecast, also below the normal seasonal run-rate. Guidance achievement requires Q4 revenue of ¥64.0bn and operating income of ¥6.1bn, implying a Q4 operating margin of approximately 9.5%, compared with 4.4% for the cumulative nine-month period. This required margin step-up is substantial and makes the forecast sensitive to gross-margin recovery and any seasonality in the business mix. The prescribed full-year forecast implies 15.1% year-on-year operating-income growth, in sharp contrast to the Q3 cumulative decline, so execution in the final quarter is pivotal. The sharp reduction in extraordinary losses supports owner-profit growth this year, but it is not a recurring growth driver. For the pharmacy sector, changes in dispensing-fee schedules, drug-price revisions, generic-drug procurement conditions, and pharmacist labor costs can rapidly affect gross-profit conversion. Sustainable growth would therefore be better evidenced by stabilization of the gross margin and operating margin than by revenue growth alone.

Financial Health

Liquidity requires explicit caution: the current ratio is 0.76x and the quick ratio is 0.68x, both below 1.0x. Current liabilities of ¥81.9bn exceed current assets of ¥62.2bn, resulting in negative working capital of ¥19.7bn. Cash and deposits of ¥21.1bn cover 1.33x short-term loans of ¥15.8bn, which provides a meaningful immediate cash buffer. However, current maturities and other current obligations leave the overall short-term liability structure more demanding than the cash-to-short-term-loan metric alone suggests. The short-term debt ratio is 53.4%, above the 40% refinancing-risk threshold, and indicates reliance on continued access to short-term borrowing facilities. Total interest-bearing debt is ¥29.6bn, comprising ¥15.8bn of short-term loans and ¥13.8bn of long-term loans. The debt-to-equity ratio is 1.76x, elevated but below the 2.0x aggressive-leverage warning threshold. Debt-to-capital of 34.3% remains within the stated sub-40% investment-grade benchmark. Interest coverage of 36.63x is strong and shows that present operating earnings can service reported interest expense comfortably. Accounts receivable increased 25.6% to ¥26.9bn, while inventories increased 51.2% to ¥6.8bn; these changes warrant monitoring against sales growth of 9.0%. Trade payables increased 31.2% to ¥40.3bn, partly financing the increased receivables and inventory but adding to the short-term funding dependence. Long-term loans declined 28.2% to ¥13.8bn, while short-term loans rose 17.0% to ¥15.8bn, reinforcing the maturity-mismatch and refinancing-risk alert. Equity declined 8.8% year on year to ¥56.7bn, reducing the equity cushion while liabilities increased. Goodwill of ¥36.8bn equals 65.0% of equity, and intangible assets of ¥66.2bn represent 42.3% of assets, making capital adequacy materially dependent on the recoverability of acquired business values. Asset retirement obligations of ¥1.2bn are recognized within the balance sheet and represent a continuing location-restoration obligation.

Notable B/S Changes

Inventories: +¥2.3bn (+51.2%) to ¥6.8bn - increased materially faster than revenue growth; monitor inventory productivity and cash absorption. Accounts receivable: +¥5.5bn (+25.6%) to ¥26.9bn - receivables growth exceeded sales growth, increasing collection-timing and working-capital sensitivity. Accounts payable: +¥9.6bn (+31.2%) to ¥40.3bn - supplier financing expanded materially and supports short-term funding, but creates sensitivity to payment-term normalization. Long-term loans: -¥5.4bn (-28.2%) to ¥13.8bn - long-term borrowings declined while short-term loans rose, increasing the proportion of debt requiring near-term refinancing. Goodwill: ¥36.8bn, equivalent to 65.0% of equity and 23.5% of assets - acquisition value remains a major balance-sheet concentration and impairment-risk monitoring item. Intangible assets: ¥66.2bn, equivalent to 42.3% of assets - high intangible concentration increases dependence on the sustained recoverability of acquired business value.

Cash Flow Quality

Cash-flow conversion cannot be quantified from the supplied financial figures. As a result, OCF-to-net-income, free-cash-flow, accruals, and cash conversion ratios are not assessed. Balance-sheet movements nevertheless identify areas that would be important for subsequent cash-flow review. Accounts receivable rose by ¥5.5bn year on year, materially faster than revenue, which can absorb operating cash if collection timing does not normalize. Inventories rose by ¥2.3bn, also faster than sales, increasing the amount of capital tied up in working capital. Trade payables increased by ¥9.6bn, more than offsetting the receivables and inventory increase on a balance-sheet movement basis. This supplier-financing effect can support near-term operating cash flow but may reverse if payment terms normalize or purchasing levels decline. The ¥19.7bn negative working-capital position makes ongoing cash generation and credit-facility access important to liquidity management. Cash and deposits declined by ¥5.7bn year on year to ¥21.1bn, despite the increase in trade payables, underscoring the need to monitor actual operating cash generation and investment outflows. No conclusion on free-cash-flow coverage of dividends or acquisition spending is drawn without reported operating, investing, and financing cash flows.

Dividend Sustainability

The declared interim dividend is ¥23.00 per share. The full-year dividend forecast is ¥46.00 per share, indicating an unchanged ¥23.00 per-share amount for the year-end payment if achieved. Based on forecast EPS of ¥186.51, the forecast dividend payout ratio is approximately 24.7%. This is comfortably below the 60% sustainability benchmark and leaves an earnings buffer under the company forecast. At Q3, the interim dividend represents approximately 18.5% of cumulative EPS of ¥124.46. The reported 19.2% payout calculation likewise reflects only the declared interim dividend relative to the supplied earnings base. Dividend affordability from accounting earnings is therefore presently sound. However, the low current ratio, negative working capital, and elevated short-term debt share mean that cash-flow generation and refinancing capacity are more relevant than the payout ratio alone. The acquisition-related intangible concentration also makes preservation of recurring earnings important for maintaining dividend capacity. No assessment of free-cash-flow coverage or total return ratio is made from the available figures.

Risk Assessment

Business risks include Gross-margin risk: gross margin fell 214bp to 13.2%, and further pressure from reimbursement revisions, drug-price changes, procurement conditions, or mix could reduce earnings disproportionately., Pharmacy-sector regulatory risk: dispensing-fee revisions and healthcare-policy changes can affect revenue and profitability independently of prescription volume growth., Labor-cost and pharmacist-availability risk: a low 4.4% operating margin provides limited protection against wage inflation or staffing shortages., Guidance execution risk: Q4 requires approximately ¥6.1bn of operating income and a roughly 9.5% operating margin to meet full-year guidance..

Financial risks include Liquidity risk: the current ratio of 0.76x, quick ratio of 0.68x, and negative working capital of ¥19.7bn indicate dependence on operating cash receipts, supplier credit, and funding access., Refinancing risk: 53.4% of interest-bearing debt is short term, above the stated 40% warning level, while short-term loans increased to ¥15.8bn., Acquisition-value risk: goodwill equals 65.0% of equity and intangible assets equal 42.3% of assets; under JGAAP, both amortization and potential impairment can weigh on earnings and equity., Working-capital risk: receivables and inventory increased faster than revenue, while payables expanded sharply, increasing sensitivity to collection and supplier-payment timing..

Key concerns include The low 13.2% gross margin and 4.4% EBIT margin are the most immediate operating concerns because revenue growth is not translating into higher recurring earnings., The high effective tax rate of 43.5% and 0.498 tax burden constrain earnings conversion from pre-tax profit., Owner profit growth was supported by lower non-controlling interests and lower extraordinary losses, whereas operating and ordinary income declined., Strong 36.63x interest coverage and a 34.3% debt-to-capital ratio moderate near-term solvency risk, but do not eliminate the liquidity and refinancing concerns..

Investment Implications

Key takeaways include Top-line momentum is positive, with nine-month revenue up 9.0%, but profitability has weakened materially., The operating-margin decline to 4.4% and gross-margin decline to 13.2% are more informative of current earnings momentum than the 32.6% increase in owner-attributable profit., Reported annualized ROE of 11.0% is within the 10-15% good range, but it is driven by asset turnover and 2.76x leverage rather than a strong net margin., Balance-sheet flexibility is constrained by sub-1.0x liquidity ratios, a high short-term debt mix, and sizable goodwill and intangible-asset exposure., The full-year forecast embeds a large Q4 operating-profit recovery, raising the importance of final-quarter margin execution..

Metrics to watch include Gross margin and operating margin versus the Q3 levels of 13.2% and 4.4%, Q4 operating-income delivery relative to the ¥6.1bn implied requirement for full-year guidance, Accounts receivable, inventories, and trade payables relative to revenue growth, Current ratio, cash balance, short-term loans, and the short-term debt ratio, Goodwill and intangible-asset balances, associated JGAAP amortization, and any impairment charges, Effective tax rate and the share of earnings attributable to non-controlling interests.

Regarding relative positioning, The company combines solid revenue scale and asset turnover with thin margins, elevated leverage-dependent returns, and a balance sheet more exposed to acquired intangible value than a conservatively financed peer. Its strong interest coverage is a relative credit strength, while weak liquidity and the substantial Q4 profit recovery embedded in guidance are relative constraints.